This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción ALBO
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Competidores de Albireo Pharma, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$44.15 |
| Máximo en las últimas 52 semanas | US$45.23 |
| Mínimo de 52 semanas | US$16.02 |
| Beta | 1.04 |
| 1Cambio en 1 mes | -1.23% |
| Variación en 3 meses | 85.66% |
| Cambio de 1 año | 66.73% |
| 3Variación en 3 años | 98.69% |
| Variación en 5 años | 28.53% |
| Variación desde la OPV | 202.40% |
Noticias y actualizaciones recientes
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Rentabilidad de los accionistas
| ALBO | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 1.2% | -3.0% | 0.9% |
| 1Y | 66.7% | 19.2% | 32.4% |
Rentabilidad vs. Industria: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.
Rentabilidad vs. Mercado: ALBO exceeded the US Market which returned -9.2% over the past year.
Volatilidad de los precios
| ALBO volatility | |
|---|---|
| ALBO Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: ALBO's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: ALBO's weekly volatility has increased from 17% to 27% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Resumen de fundamentos de Albireo Pharma, Inc.
| Estadísticas fundamentales de ALBO | |
|---|---|
| Capitalización bursátil | US$921.13m |
| Beneficios(TTM) | -US$131.14m |
| Ingresos (TTM) | US$57.39m |
16.1x
Ratio precio-ventas (PS)-7.0x
Ratio precio-beneficio (PE)¿Está ALBO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ALBO | |
|---|---|
| Ingresos | US$57.39m |
| Coste de los ingresos | US$2.55m |
| Beneficio bruto | US$54.84m |
| Otros gastos | US$185.99m |
| Beneficios | -US$131.14m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -6.29 |
| Margen bruto | 95.56% |
| Margen de beneficio neto | -228.51% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ALBO a largo plazo?
Ver rendimiento histórico y comparativa